Marker Therapeutics, Inc. (MRKR) - Dilution Analysis

10-K filing | 15.3M shares outstanding

10-Q filing | 11.1M shares outstanding

10-K filing | 10.7M shares outstanding

8-K filing: On February 12, 2024, the Company's Board of Directors approved a discretionary award of 30,000 stock options to each of David Eansor, Katherine Knobil and Steven Elms under the Plan.

S-3 filing: This prospectus relates to the resale, from time to time, of up to 10,062,500 shares of our common stock, by the selling stockholders.

8-K filing: Marker Therapeutics, Inc. closed a private placement on December 23, 2024, issuing 1,783,805 shares of Common Stock and warrants to purchase additional shares for gross proceeds of approximately $16.1 million. ($16.1M proceeds)

8-K filing: Marker Therapeutics, Inc. entered into a securities purchase agreement for a private placement expected to provide gross proceeds of $16.1 million, selling 5,031,250 shares of its common stock (or pre-funded warrants) and accompanying warrants. ($16.1M proceeds)

S-3 filing: The company is filing an S-3 to offer Common Stock, Preferred Stock, Debt Securities and Warrants from time to time for a total amount of $300,000,000.

10-Q filing | 8.9M shares outstanding

10-Q filing | 8.9M shares outstanding

10-Q filing | 8.9M shares outstanding

10-K filing | 8.8M shares outstanding

10-Q filing | 8.8M shares outstanding

10-Q filing | 8.8M shares outstanding

10-Q filing | 8.7M shares outstanding

10-K filing | 8.4M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 83,599,187 → 8,359,918

S-1 filing: This S-1 filing relates to the offer and sale of up to 25,770,990 shares of common stock by Lincoln Park Capital Fund, LLC, including shares that may be issued and sold to Lincoln Park under a common stock purchase agreement for up to $25,000,000.

8-K filing: Marker Therapeutics, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $25,000,000 of shares of its common stock over a 24-month period, and issued 1,804,098 Commitment Shares to Lincoln Park as consideration for its commitment.

10-Q filing | 83.6M shares outstanding

10-Q filing | 83.6M shares outstanding

10-Q filing | 83.1M shares outstanding

10-K filing | 76.5M shares outstanding

10-Q filing | 83.1M shares outstanding

S-3 filing: The filing is an S-3 form for a shelf offering of common stock, preferred stock, debt securities, and warrants, with a total offering amount of up to $300,000,000. Additionally, the company is offering common stock through an 'at the market offering' that may be made from time to time through our Sales Agents with an aggregate offering price of up to $75,000,000.

10-Q filing | 83.0M shares outstanding

10-Q filing | 83.0M shares outstanding

8-K filing: Marker Therapeutics, Inc. completed a public offering of 28,572,000 shares of common stock at $1.75 per share, with the underwriters partially exercising their option to purchase an additional 3,710,857 shares, resulting in gross proceeds of approximately $56.5 million. ($56.5M proceeds)

10-K filing | 47.0M shares outstanding

10-Q filing | 46.9M shares outstanding

10-Q filing | 46.6M shares outstanding

10-Q filing | 45.5M shares outstanding

10-K filing | 46.5M shares outstanding